We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF
IHE

102 hedge funds and large institutions have $311M invested in iShares US Pharmaceuticals ETF in 2014 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 31 increasing their positions, 30 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

425% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 4

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

20% more capital invested

Capital invested by funds: $259M → $311M (+$52.1M)

19% more funds holding

Funds holding: 86 → 102 (+16)

6.69% more ownership

Funds ownership: 105.34% → 112.03% (+6.7%)

3% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 30

Holders
102
Holders Change
+16
Holders Change %
+18.6%
% of All Funds
2.72%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
21
Increased
31
Reduced
30
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BCM
Brookstone Capital Management
Illinois
+$15.1M
2
BWM
Braver Wealth Management
Massachusetts
+$11.9M
3
Citadel Advisors
Citadel Advisors
Florida
+$4.2M
4
Wells Fargo
Wells Fargo
California
+$3.46M
5
SG Americas Securities
SG Americas Securities
New York
+$2.83M

Top Sellers

Rank Fund Capital Flow
1
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$12.1M
2
RJA
Raymond James & Associates
Florida
-$2.76M
3
TRCT
Tower Research Capital (TRC)
New York
-$2.6M
4
Bank of America
Bank of America
North Carolina
-$2.3M
5
Morgan Stanley
Morgan Stanley
New York
-$810K
Name Holding Trade Value Shares
Change 		Change in
Stake
US Bancorp
51
US Bancorp
Minnesota
$651K – – –
SI
52
SII Investments
Wisconsin
$625K +$588K +12,075 New
PAS
53
Partnervest Advisory Services
California
$566K +$20.5K +420 +4%
TYCC
54
Texas Yale Capital Corp
Florida
$564K – – –
LSA
55
L & S Advisors
California
$516K -$2.92K -60 -0.6%
HSBC Holdings
56
HSBC Holdings
United Kingdom
$514K – – –
WA
57
WFG Advisors
Texas
$483K +$10.7K +219 +2%
Ameriprise
58
Ameriprise
Minnesota
$463K +$174K +3,564 +64%
UCFA
59
United Capital Financial Advisors
Texas
$454K – – –
CB
60
Commerce Bank
Missouri
$453K -$63.6K -1,305 -13%
Envestnet Asset Management
61
Envestnet Asset Management
Illinois
$450K +$421K +8,649 +3,314%
PAG
62
Private Advisor Group
New Jersey
$419K -$141K -2,895 -26%
Deutsche Bank
63
Deutsche Bank
Germany
$418K +$43.9K +900 +12%
GA
64
Gateway Advisory
New Jersey
$406K – – –
William Blair & Company
65
William Blair & Company
Illinois
$393K – – –
Creative Planning
66
Creative Planning
Kansas
$383K +$130K +2,658 +54%
CCM
67
Condor Capital Management
New Jersey
$334K -$5.85K -120 -2%
Cambridge Investment Research Advisors
68
Cambridge Investment Research Advisors
Iowa
$334K -$1.17K -24 -0.4%
TH
69
Timber Hill
Connecticut
$316K +$305K +6,252 New
DC
70
Davenport & Co
Virginia
$294K – – –
JMPWA
71
JP Morgan Private Wealth Advisors
California
$281K -$11K -225 -4%
SI
72
Stephens Inc
Arkansas
$278K +$5.85K +120 +2%
BI
73
Boulegeris Investments
Georgia
$276K +$585 +12 +0.2%
BFS
74
Bradley Foster & Sargent
Connecticut
$273K – – –
EFS
75
Essex Financial Services
Connecticut
$267K – – –
1 2
3
4 5

IHE Hedge Fund Activity: Q4 2014 in Review

102 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q4 2014, worth a combined $311M — up 20% from $259M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new IHE positions and 4 closed out — a net gain of 17 holders — while 31 added to existing stakes and 30 trimmed.

The largest buyer was Brookstone Capital Management, opening a new position worth an estimated $15.1M. The largest seller was Bank of Montreal, cutting an estimated $12.1M.

  • 102 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q4 2014, up from 86 in Q3 2014.
  • Funds reported $311M of iShares US Pharmaceuticals ETF stock for Q4 2014, up 20% quarter-over-quarter.
  • 21 funds opened new iShares US Pharmaceuticals ETF positions in Q4 2014 and 4 closed out, a net change of +17 holders.
  • The largest iShares US Pharmaceuticals ETF buyer in Q4 2014 was Brookstone Capital Management, an estimated $15.1M added.
  • The largest iShares US Pharmaceuticals ETF seller in Q4 2014 was Bank of Montreal, an estimated $12.1M sold.

Based on aggregated 13F filings for Q4 2014.